Drugs / CV-MG01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02609022 | Mar 2016 → Sep 2018 | myasthenia gravis | CuraVac | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03165435 | Jul 2018 → Oct 2019 | generalized myasthenia gravis | CuraVac | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV-MG01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02609022 ↗ |
| Modality | Vaccine | “The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis” NCT02609022 ↗ |
| Route | Subcutaneous | “3 consecutive subcutaneous injections of CV-MG01” NCT02609022 ↗ |